ADPT Stock - Adaptive Biotechnologies Corporation
Unlock GoAI Insights for ADPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $178.96M | $170.28M | $185.31M | $154.34M | $98.38M |
| Gross Profit | $106.88M | $94.72M | $127.40M | $105.04M | $75.85M |
| Gross Margin | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% |
| Operating Income | $-162,549,000 | $-227,035,000 | $-200,186,000 | $-208,966,000 | $-152,817,000 |
| Net Income | $-159,492,000 | $-225,250,000 | $-200,191,000 | $-207,279,000 | $-146,227,000 |
| Net Margin | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% |
| EPS | $-1.08 | $-1.56 | $-1.00 | $-1.46 | $-1.06 |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Equal Weight | $21 |
| September 30th 2025 | Guggenheim | Initiation | Buy | $20 |
| June 18th 2025 | Craig Hallum | Initiation | Buy | $15 |
| March 21st 2025 | Goldman | Upgrade | Buy | $9 |
| July 5th 2023 | JP Morgan | Resumed | Overweight | $15 |
| January 5th 2023 | Scotiabank | Initiation | Sector Outperform | $15 |
| December 21st 2022 | Piper Sandler | Upgrade | Overweight | $14← $7.5 |
| August 25th 2022 | Credit Suisse | Initiation | Underperform | $8 |
| June 3rd 2022 | Piper Sandler | Initiation | Neutral | $7.5 |
Earnings History & Surprises
ADPTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.24 | $-0.17 | +29.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.28 | $-0.20 | +28.6% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $-0.27 | $-0.23 | +14.8% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.30 | $-0.22 | +26.7% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.35 | $-0.33 | +5.7% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $-0.32 | $-0.30 | +6.3% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $-0.33 | $-0.33 | 0.0% | = MET |
Q2 2023 | May 3, 2023 | $-0.34 | $-0.40 | -17.6% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-0.37 | $-0.28 | +24.3% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.40 | $-0.37 | +7.5% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.43 | $-0.44 | -2.3% | ✗ MISS |
Q1 2022 | Feb 15, 2022 | $-0.43 | $-0.43 | 0.0% | = MET |
Q4 2021 | Nov 3, 2021 | $-0.43 | $-0.40 | +7.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.43 | $-0.35 | +18.6% | ✓ BEAT |
Latest News
Adaptive Biotechnologies Announces 2 Immune Receptor Licensing Agreements With Pfizer; Co Gets Undisclosed Upfront Payment, Potential Commercial And Sales Milestones Of Up To $890M
📈 PositiveReported Saturday, Adaptive Highlights clonoSEQ MRD Monitoring Helping Tailor Treatment Intensity Or Duration With Precision Across Hematology-Oncology Care Pathways
📈 PositiveAdaptive Biotechnologies Sees Its Cancer Test Featured in 89 Studies at Major Blood Disease Conference
📈 PositiveMorgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $16
➖ NeutralJP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $20
📈 PositiveCORRECTION: Adaptive Biotechnologies Q3 Adj. EPS $(0.15), Inline, Sales $60.200M Miss $64.643M Estimate
📉 NegativeAdaptive Biotechnologies Q3 EPS $0.06 May Not Compare To $(0.17) Estimate, Sales $94.000M May Not Compare To $64.643M Estimate
📈 PositiveBTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $19
📈 PositiveAdaptive Biotechnologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $15 to $20.
📈 PositivePiper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $20
📈 PositiveJP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $17
📈 PositiveAdaptive Biotechnologies shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $20 price target.
📈 PositiveGuggenheim Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $20
📈 PositiveFrequently Asked Questions about ADPT
What is ADPT's current stock price?
What is the analyst price target for ADPT?
What sector is Adaptive Biotechnologies Corporation in?
What is ADPT's market cap?
Does ADPT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ADPT for comparison